前列地尔联合奥曲肽治疗肝肾综合征

Alprostadil and Octreotide Treat Hepatorenal Syndrome

目的探讨前列地尔联合奥曲肽治疗肝肾综合征疗效。方法对2008年1月至2013年10月42例肝肾综合征患者随机分为治疗组和对照组,两组均同时采用基础治疗加前列地尔10μg/d。治疗组在对照组的基础上加用奥曲肽0.1 mg ih q8h/d,观察患者的临床症状、腹水减少情况以及肾功能指标。结果治疗组总有效率(71.43%)、腹水减少及肾功能好转均明显优于对照组(38.10%)(P<0.05)。结论前列地尔联合奥曲肽治疗肝肾综合征疗效明显优于前列地尔。

Objective To observe the effect of octretide combined alprostadil on hepatorenal syndrome. Methods 42 patients of hepatorenal syndrome were randomized into the treat and control groups. In addition, to routine management, the patients in the treat group were given octretide 0.1 mg ih q8h/d, while the control group was only given alprostadil 10 μg/d during the period of the treatment. Patient＇s clinical symptoms, abdomen and renal function were observed. Result After treatment, the total effective rate, ascites reduce and renal function were significant between the two gyoups. Conclusion The octretide combined with alprostadil in the treatment of hepatorenal syndrome was efficacy, better effect than single alprostadil.